Incyte Corporation

82.58-4.95-5.66%Vol 2.67M1Y Perf -8.89%
Jun 11th, 2021 16:00 DELAYED
BID82.00 ASK83.30
Open84.67 Previous Close87.53
Pre-Market- After-Market82.58
 - -  - -%
Target Price
97.10 
Analyst Rating
Moderate Buy 2.07
Potential %
17.58 
Finscreener Ranking
★★★★★     59.55
Insiders Trans % 3/6/12 mo.
-100/-85/-96 
Value Ranking
★★★★+     58.16
Insiders Value % 3/6/12 mo.
-100/-68/-96 
Growth Ranking
★★★★★     81.22
Insiders Shares Cnt. % 3/6/12 mo.
-100/-62/-95 
Income Ranking
 —    -
Market Cap18.16B 
Earnings Rating
Sell
Price Range Ratio 52W %
20.26 
Earnings Date
3rd Aug 2021

Today's Price Range

81.0685.00

52W Range

75.52110.36

5 Year PE Ratio Range

-36.305.50K

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-0.90%
1 Month
0.25%
3 Months
4.52%
6 Months
1.57%
1 Year
-8.89%
3 Years
17.00%
5 Years
2.70%
10 Years
370.01%

TickerPriceChg.Chg.%
INCY82.58-4.9500-5.66
AAPL127.351.24000.98
GOOG2 513.93-7.6700-0.30
MSFT257.890.65000.25
XOM62.17-0.5800-0.92
WFC45.680.59001.31
JNJ164.96-2.1200-1.27
FB331.26-1.2000-0.36
GE13.690.06000.44
JPM160.29-0.1100-0.07
Financial StrengthValueIndustryS&P 500US Markets
3.80
4.00
0.01
0.01
281.30
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
95.10
20.10
22.00
7.90
18.65
RevenueValueIndustryS&P 500US Markets
2.70B
12.29
17.79
23.64
Earnings HistoryEstimateReportedSurprise %
Q01 20210.420.5019.05
Q04 20200.650.7312.31
Q03 20200.480.03-93.75
Q02 20200.681.0452.94
Q01 20200.31-3.05-1 083.87
Q04 20190.540.50-7.41
Q03 20190.570.628.77
Q02 20190.380.5647.37
Earnings Per EndEstimateRevision %Trend
6/2021 QR0.56-9.68Negative
9/2021 QR0.47-20.34Negative
12/2021 FY2.20-7.56Negative
12/2022 FY3.48-1.69Negative
Next Report Date3rd Aug 2021
Estimated EPS Next Report0.56
Estimates Count4
EPS Growth Next 5 Years %36.00
Volume Overview
Volume2.67M
Shares Outstanding219.92M
Trades Count29.40K
Dollar Volume93.57M
Avg. Volume1.23M
Avg. Weekly Volume1.24M
Avg. Monthly Volume1.02M
Avg. Quarterly Volume1.17M

Incyte Corporation (NASDAQ: INCY) stock closed at 82.58 per share at the end of the most recent trading day (a -5.66% change compared to the prior day closing price) with a volume of 2.68M shares and market capitalization of 18.16B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1773 people. Incyte Corporation CEO is Herve Hoppenot.

The one-year performance of Incyte Corporation stock is -8.89%, while year-to-date (YTD) performance is -5.06%. INCY stock has a five-year performance of 2.7%. Its 52-week range is between 75.52 and 110.36, which gives INCY stock a 52-week price range ratio of 20.26%

Incyte Corporation currently has a PE ratio of 38.20, a price-to-book (PB) ratio of 6.72, a price-to-sale (PS) ratio of 6.93, a price to cashflow ratio of 23.90, a PEG ratio of 2.32, a ROA of 14.69%, a ROC of 20.12% and a ROE of 20.20%. The company’s profit margin is 18.65%, its EBITDA margin is 22.00%, and its revenue ttm is $2.70 Billion , which makes it $12.29 revenue per share.

Of the last four earnings reports from Incyte Corporation, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.56 for the next earnings report. Incyte Corporation’s next earnings report date is 03rd Aug 2021.

The consensus rating of Wall Street analysts for Incyte Corporation is Moderate Buy (2.07), with a target price of $97.1, which is +17.58% compared to the current price. The earnings rating for Incyte Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Incyte Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Incyte Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 12.84, ATR14 : 2.30, CCI20 : -35.45, Chaikin Money Flow : -0.03, MACD : 0.55, Money Flow Index : 46.09, ROC : -0.12, RSI : 46.57, STOCH (14,3) : 23.07, STOCH RSI : 0.00, UO : 50.48, Williams %R : -76.93), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Incyte Corporation in the last 12-months were: Barry P. Flannelly (Option Excercise at a value of $1 538 374), Barry P. Flannelly (Sold 30 325 shares of value $2 804 405 ), Dashyant Dhanak (Option Excercise at a value of $535 463), Dashyant Dhanak (Sold 7 348 shares of value $671 766 ), Herve Hoppenot (Buy at a value of $1 000 007), Herve Hoppenot (Option Excercise at a value of $19 716 404), Herve Hoppenot (Sold 269 313 shares of value $29 624 430 ), Jean-Jacques Bienaime (Sold 798 shares of value $66 234 ), Jonathan Elliott Dickinson (Sold 9 000 shares of value $947 790 ), Maria E Pasquale (Option Excercise at a value of $418 789), Maria E Pasquale (Sold 5 039 shares of value $476 675 ), Maria E. Pasquale (Option Excercise at a value of $427 090), Maria E. Pasquale (Sold 5 039 shares of value $476 675 ), Michael James Morrissey (Sold 20 000 shares of value $1 621 600 ), Paul Trower (Option Excercise at a value of $448 171), Paul Trower (Sold 6 943 shares of value $763 730 ), Steven H. Stein (Option Excercise at a value of $3 046 166), Steven H. Stein (Sold 45 017 shares of value $4 830 757 ), Vijay K. Iyengar (Option Excercise at a value of $873 009), Vijay K. Iyengar (Sold 16 577 shares of value $1 720 878 ), Wendy L. Dixon (Option Excercise at a value of $379 400), Wendy L. Dixon (Sold 20 000 shares of value $1 890 200 ), Wenqing Yao (Option Excercise at a value of $2 645 805), Wenqing Yao (Sold 38 098 shares of value $3 930 968 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (46.67 %)
7 (46.67 %)
7 (43.75 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
8 (53.33 %)
8 (53.33 %)
9 (56.25 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.07
Moderate Buy
2.07
Moderate Buy
2.13

Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.

CEO: Herve Hoppenot

Telephone: +1 302 498-6700

Address: 1801 Augustine Cut-Off, Wilmington 19803, DE, US

Number of employees: 1 773

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

60%40%

Bearish Bullish

60%40%

News

Stocktwits